India Life Sciences Fund II to be launched by March

Currently at advanced stage of discussion with a pharma company to invest from second fund

(EILSF) II, a fund focused on investing in the life sciences space in India, is expected to be launched by March 2013.

The first fund - Evolvence India Life Sciences Fund of $100 million - is exhausted and was invested across eight companies.
"The second fund, India Life Sciences Fund II which is slightly bigger than the first fund at $150 million, is currently in the pipeline. We are ready to start investing from the second fund by the first quarter of next calendar year," Hari Buggana, managing director of InvAscent – the investment advisor of Evolvence India Life Sciences Fund, told Business Standard.

"Currently, we are in the advanced stage discussion with a pharma company to invest from the second fund, which is likely to happen by March,"

EILSF, the Mauritius-based PE (private equity) fund which was established in 2006, invested in eight including five pharma companies, two healthcare and one med-tech company since operation. Its investments include d Rs 35 crore in Sutures India Private Limited, Rs 25 crore in Chennai-based Anjan Drugs, Health Care Global and Gland Pharma. In December last year, EILSF acquired 21.05% stake in Thane-based Fermenta Biotech for Rs 40 crore.

The second fund will provide growth capital to established and mid-sized companies in pharmaceutical, medical device, biopharmaceutical, contract R&D, and medical services segments. "We expect to deploy the second fund in similar number of companies over the next three years," he said.

India is emerging as one of the global champions in providing low-cost, high-quality hospitals. Unlike, IT companies, India itself is a huge untapped market for the healthcare and pharma companies.

"Currently, India has about 1-1.2 beds per 10,000 people, while China has four beds and US has seven beds. To improve the healthcare infrastructure in India where China is today, India will require about $50 billion funding," he said.

"The private equity landscape will continue to grow in India, as the market is still niche. Compared to that private equity across all the sectors is still a drop in the bucket in India," he added.

image
Business Standard
177 22
Business Standard

India Life Sciences Fund II to be launched by March

Currently at advanced stage of discussion with a pharma company to invest from second fund

Itishree Samal  |  Hyderabad 



(EILSF) II, a fund focused on investing in the life sciences space in India, is expected to be launched by March 2013.

The first fund - Evolvence India Life Sciences Fund of $100 million - is exhausted and was invested across eight companies.
"The second fund, India Life Sciences Fund II which is slightly bigger than the first fund at $150 million, is currently in the pipeline. We are ready to start investing from the second fund by the first quarter of next calendar year," Hari Buggana, managing director of InvAscent – the investment advisor of Evolvence India Life Sciences Fund, told Business Standard.

"Currently, we are in the advanced stage discussion with a pharma company to invest from the second fund, which is likely to happen by March,"


EILSF, the Mauritius-based PE (private equity) fund which was established in 2006, invested in eight including five pharma companies, two healthcare and one med-tech company since operation. Its investments include d Rs 35 crore in Sutures India Private Limited, Rs 25 crore in Chennai-based Anjan Drugs, Health Care Global and Gland Pharma. In December last year, EILSF acquired 21.05% stake in Thane-based Fermenta Biotech for Rs 40 crore.

The second fund will provide growth capital to established and mid-sized companies in pharmaceutical, medical device, biopharmaceutical, contract R&D, and medical services segments. "We expect to deploy the second fund in similar number of companies over the next three years," he said.

India is emerging as one of the global champions in providing low-cost, high-quality hospitals. Unlike, IT companies, India itself is a huge untapped market for the healthcare and pharma companies.

"Currently, India has about 1-1.2 beds per 10,000 people, while China has four beds and US has seven beds. To improve the healthcare infrastructure in India where China is today, India will require about $50 billion funding," he said.

"The private equity landscape will continue to grow in India, as the market is still niche. Compared to that private equity across all the sectors is still a drop in the bucket in India," he added.

RECOMMENDED FOR YOU

India Life Sciences Fund II to be launched by March

Currently at advanced stage of discussion with a pharma company to invest from second fund

The first fund - Evolvence India Life Sciences Fund of $100 million - is exhausted and was invested across eight companies.

(EILSF) II, a fund focused on investing in the life sciences space in India, is expected to be launched by March 2013.

The first fund - Evolvence India Life Sciences Fund of $100 million - is exhausted and was invested across eight companies.
"The second fund, India Life Sciences Fund II which is slightly bigger than the first fund at $150 million, is currently in the pipeline. We are ready to start investing from the second fund by the first quarter of next calendar year," Hari Buggana, managing director of InvAscent – the investment advisor of Evolvence India Life Sciences Fund, told Business Standard.

"Currently, we are in the advanced stage discussion with a pharma company to invest from the second fund, which is likely to happen by March,"

EILSF, the Mauritius-based PE (private equity) fund which was established in 2006, invested in eight including five pharma companies, two healthcare and one med-tech company since operation. Its investments include d Rs 35 crore in Sutures India Private Limited, Rs 25 crore in Chennai-based Anjan Drugs, Health Care Global and Gland Pharma. In December last year, EILSF acquired 21.05% stake in Thane-based Fermenta Biotech for Rs 40 crore.

The second fund will provide growth capital to established and mid-sized companies in pharmaceutical, medical device, biopharmaceutical, contract R&D, and medical services segments. "We expect to deploy the second fund in similar number of companies over the next three years," he said.

India is emerging as one of the global champions in providing low-cost, high-quality hospitals. Unlike, IT companies, India itself is a huge untapped market for the healthcare and pharma companies.

"Currently, India has about 1-1.2 beds per 10,000 people, while China has four beds and US has seven beds. To improve the healthcare infrastructure in India where China is today, India will require about $50 billion funding," he said.

"The private equity landscape will continue to grow in India, as the market is still niche. Compared to that private equity across all the sectors is still a drop in the bucket in India," he added.

image
Business Standard
177 22
Widgets Magazine

More News

  • Monsanto Monsanto lobbies with US lawmakers
  • Sachin Bansal & Binny Bansal, Flipkart Flipkart improves customer service
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard